Atom Bioscience is a research-based pharmaceutical company engaged in new drug discovery and development on treatments for inflammatory and metabolic diseases.
Among our drugs now in development is ABP-671, a novel compound for chronic gout treatment. ABP-671 has completed Phase 1 clinical trials in the United States and 2a clinical trials in Australia and China. Atom Bioscience is advancing ABP-671 to global Phase 3 trials and commercialization.
Our novel compound ABP-745 is currently in Phase 1 clinical trials for acute gout. Other pipelines are under pre-clinical development and expected to enter clinical trials soon.
Atom Bioscience Management Team
Atom Bioscience Investors
Since 2012, Dr. Shi and his experienced management team have raised nearly $170 million USD to advance ABP-671 and ABP-745 along with other compounds in the company’s pipeline. The company closed its latest round of financing, a Series D, in October, 2023 for approximately $83 million USD led by Kaitai Capital.